Jade Biosciences, Inc. 8-K

What Happened

• Jade Biosciences, Inc. announced in an 8-K (filed Jan 5, 2026) that its preliminary, unaudited cash, cash equivalents and investments were approximately $336 million as of December 31, 2025. The company said this level of liquidity is expected to fund operations into the first half of 2028. Jade also issued a press release on January 5, 2026 with business updates ahead of the 44th Annual J.P. Morgan Healthcare Conference (Jan 12–15, 2026) and posted an updated corporate presentation on its website.

Key Details

• Preliminary cash balance: ~ $336 million as of Dec 31, 2025.
• Runway: Company expects funds to support operations into the first half of 2028.
• Status of figures: Quarter-end close not complete; amounts are preliminary, unaudited and subject to change pending close and audit. Independent auditors have not reviewed these preliminary amounts.
• Disclosure actions: Press release issued Jan 5, 2026 and corporate presentation posted online; company will use its website for future presentation updates and will not file an 8-K for every update.

Why It Matters

• Cash runway is a key indicator of how long Jade can fund operations and ongoing development programs without raising additional capital. The ~$336M preliminary balance and the stated runway into H1 2028 provide investors a snapshot of near-term financial flexibility. However, because the figures are preliminary and unaudited, investors should treat them as estimates until the quarter close and audited financials are complete. The company’s outreach ahead of the J.P. Morgan conference signals active investor communications but does not change the preliminary nature of the financial update.